Jefferies Group LLC reaffirmed their buy rating on shares of GlycoMimetics, Inc. (NASDAQ:GLYC) in a report released on Thursday morning. They currently have a $16.00 target price on the biotechnology company’s stock.
Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of GlycoMimetics from a buy rating to a hold rating in a research note on Thursday, July 20th. Stifel Nicolaus restated a buy rating and set a $17.00 target price (up from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. SunTrust Banks, Inc. set a $21.00 target price on shares of GlycoMimetics and gave the stock a buy rating in a research note on Monday, August 7th. BidaskClub upgraded shares of GlycoMimetics from a sell rating to a hold rating in a research note on Wednesday, August 9th. Finally, Roth Capital initiated coverage on shares of GlycoMimetics in a research note on Monday. They issued a buy rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. GlycoMimetics presently has a consensus rating of Buy and an average price target of $17.67.
Shares of GlycoMimetics (GLYC) traded up 1.78% on Thursday, hitting $10.86. 415,159 shares of the stock were exchanged. The stock’s market cap is $355.37 million. The company’s 50 day moving average is $12.46 and its 200-day moving average is $10.44. GlycoMimetics has a 52-week low of $3.82 and a 52-week high of $16.94.
GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.07. Analysts predict that GlycoMimetics will post ($1.21) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “GlycoMimetics, Inc. (GLYC) Receives “Buy” Rating from Jefferies Group LLC” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/glycomimetics-inc-glyc-receives-buy-rating-from-jefferies-group-llc.html.
In other news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $13.00, for a total transaction of $26,000.00. Following the transaction, the senior vice president now directly owns 150,615 shares in the company, valued at $1,957,995. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 43.80% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in shares of GlycoMimetics by 159.4% during the second quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock worth $1,037,000 after acquiring an additional 57,091 shares during the last quarter. Wellington Management Group LLP grew its position in shares of GlycoMimetics by 14.9% during the first quarter. Wellington Management Group LLP now owns 3,216,751 shares of the biotechnology company’s stock worth $17,467,000 after acquiring an additional 416,834 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of GlycoMimetics during the second quarter worth approximately $17,786,000. Virtu KCG Holdings LLC purchased a new position in shares of GlycoMimetics during the second quarter worth approximately $569,000. Finally, Private Capital Advisors Inc. purchased a new position in shares of GlycoMimetics during the second quarter worth approximately $446,000. Institutional investors and hedge funds own 92.62% of the company’s stock.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.